Can two cancer pills keep breast cancer from returning?

NCT ID NCT07180056

Recruiting now Disease control Sponsor: Wenjin Yin Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is looking at whether taking a CDK4/6 inhibitor (either abemaciclib or ribociclib) after surgery can help prevent breast cancer from coming back in people with HR+/HER2- breast cancer. The researchers will follow 229 participants to see how long they stay cancer-free and what side effects occur. This is a real-world study, meaning it observes routine medical care rather than a controlled experiment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CDK4/6 inhibitors (abemaciclib or ribociclib)
What this could lead to: If successful, this study could confirm that adding CDK4/6 inhibitors after surgery helps keep HR+/HER2- breast cancer from coming back.
What could go wrong: This is an observational real-world study, not a randomized controlled trial, so results may be less definitive. Side effects from these drugs can be significant, and not all patients may benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Renji Hospital, School of Medicine, Shanghai Jiaotong University
RECRUITING

Shanghai, 200127, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.